SCHEMBL8738340

SCHEMBL8738340

Cc1nc(CN2CCN(C)CC2)sc1-c1csc(Nc2cc(C(N)=O)ccc2OC(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.43
MEN1 O00255 12/20 0.43
KMT2A Q03164 12/20 0.43
ALDH1A1 P00352 10/20 0.43
KDM4E B2RXH2 9/20 0.43
HTT P42858 7/20 0.43
SMN1; SMN2 Q16637 7/20 0.43
HPGD P15428 5/20 0.43
TDP1 Q9NUW8 2/20 0.43
GAA P10253 8/20 0.42
LMNA P02545 6/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
YES1 P07947 1/20 0.42
LYN P07948 1/20 0.42
HCK P08631 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8738337 0.97 MAPT (0.41) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738380 0.94 MAPT (0.44) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738439 0.93 MAPT (0.42) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738814 0.93 MEN1 (0.43) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8738332 0.92 MAPT (0.42) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8737785 0.91 MEN1 (0.42) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8737964 0.87 MEN1 (0.44) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6113996 0.86 MAPT (0.48) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL6114066 0.86 MEN1 (0.49) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8737795 0.85 TRPV4 (0.46) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MAPT 3531/4885MEN1 2298/4885KMT2A 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.